Enhanced insulin action following subcutaneous co-administration of insulin and C-peptide in rats

Diabetes/Metabolism Research and Reviews

Volumn 30, Issue 2, 2014, Pages 124-131

  Kubota, M ^a   Sato, Y ^b   Khookhor, O ^b   Ekberg, K ^c   Chibalin, A V ^c   Wahren, J ^c  

^a KYOTO UNIVERSITY   (Japan)

^b AICHI GAKUIN UNIVERSITY   (Japan)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

C peptide; Co administration; Disaggregation; Euglycemic clamp; Insulin action; Insulin hexamers

Indexed keywords

C PEPTIDE; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; HUMAN INSULIN; INSULIN; INSULIN LISPRO; PENTAPEPTIDE; PROTEIN KINASE B; RUBIDIUM 86;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; DRUG BLOOD LEVEL; ENZYME ACTIVATION; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; INTRACELLULAR SIGNALING; LIVER; MALE; MONOTHERAPY; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SKELETAL MUSCLE;

C-PEPTIDE; CO-ADMINISTRATION; DISAGGREGATION; EUGLYCEMIC CLAMP; INSULIN ACTION; INSULIN HEXAMERS;

ANIMALS; C-PEPTIDE; CELL LINE; DRUG COMBINATIONS; DRUG IMPLANTS; DRUG THERAPY, COMBINATION; ENZYME ACTIVATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN LISPRO; INSULIN, REGULAR, HUMAN; LIVER; MALE; MUSCLE, SKELETAL; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECOMBINANT PROTEINS;

EID: 84893442181     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2471     Document Type: Article

References (23)

1. Steiner DF, Cunningham D, Spigelman L, Aten B. Insulin biosynthesis: evidence for a precursor. Science 1967; 157(789): 697-700.
2. Panero F, Novelli G, Zucco C, et al. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 2009; 32(2): 301-305.
3. Johansson BL, Sjöberg S, Wahren J. The influence of human C-peptide on renal function and glucose utilization in type 1 (insulin-dependent) diabetic patients. Diabetologia 1992; 35(2): 121-128.
4. Johansson BL, Kernell A, Sjöberg S, Wahren J. Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab 1993; 77(4): 976-981.
5. Johansson BL, Borg K, Fernqvist-Forbes E, Odergren T, Remahl S, Wahren J. C-peptide improves autonomic nerve function in IDDM patients. Diabetologia 1996; 39(6): 687-695.
6. Wahren J, Kallas A, Sima AA. The clinical potential of C-peptide replacement in type 1 diabetes. Diabetes 2012; 61(4): 761-772.
7. Shafqat J, Melles E, Sigmundsson K, et al. Proinsulin C-peptide elicits disaggregation of insulin resulting in enhanced physiological insulin effects. Cell Mol Life Sci 2006; 63(15): 1805-1811.
8. Nerelius C, Alvelius G, Jornvall H. N-terminal segment of proinsulin C-peptide active in insulin interaction/desaggregation. Biochem Biophys Res Commun 2010; 403(3-4): 462-467.
9. Landreh M, Alvelius G, Willander H, et al. Insulin solubility transitions by pH-dependent interactions with proinsulin C-peptide. FEBS J 2012; 279(24): 4589-4597.
10. Landreh M, Johansson J, Jörnvall H. Interactions of proinsulin C-peptide in the beta cell secretory granule: a molecular balance with implications for diabetes associated conditions. Hormone Metab Res 2013; 45, DOI:10.1055/s-0033-1347208
11. Li L, Oshida Y, Kusunoki M, et al. Rat C peptide I and II stimulate glucose utilization in STZ-induced diabetic rats. Diabetologia 1999; 42(8): 958-964.
12. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237(3): E214-E223.
13. Ohtomo Y, Aperia A, Sahlgren B, Johansson BL, Wahren J. C-peptide stimulates rat renal tubular Na+, K(+)-ATPase activity in synergism with neuropeptide Y. Diabetologia 1996; 39(2): 199-205.
14. +-ATPase via activation of ERK1/2 MAP kinases in human renal tubular cells. Cell Mol Life Sci 2004; 61(21): 2782-2790.
15. Jörnvall H, Lindahl E, Astorga-Wells J, et al. Oligomerization and insulin interactions of proinsulin C-peptide: threefold relationships to properties of insulin. Biochem Biophys Res Commun 2010; 391(3): 1561-1566.
16. Zhang W, Kamiya H, Ekberg K, Wahren J, Sima AA. C-peptide improves neuropathy in type 1 diabetic BB/Wor-rats. Diabetes Metab Res Rev 2007; 23(1): 63-70.
17. Vish MG, Mangeshkar P, Piraino G, et al. Proinsulin C-peptide exerts beneficial effects in endotoxic shock in mice. Crit Care Med 2007; 35(5): 1348-1355.
18. Chima RS, LaMontagne T, Piraino G, Hake PW, Denenberg A, Zingarelli B. C-peptide: a novel inhibitor of lung inflammation following hemorrhagic shock. Am J Physiol Lung Cell Mol Physiol 2011; 300(5): L730-L739.
19. Ekberg K, Brismar T, Johansson BL, et al. C-peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 2007; 30(1): 71-76.
20. Wallerath T, Kunt T, Forst T, et al. Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide 2003; 9(2): 95-102.
21. Wojcikowski C, Maier V, Dominiak K, Fussganger R, Pfeiffer EF. Effects of synthetic rat C-peptide in normal and diabetic rats. Diabetologia 1983; 25(3): 288-290.
22. Sato Y, Oshida Y, Han YQ, et al. C-peptide fragments stimulate glucose utilization in diabetic rats. Cell Mol Life Sci 2004; 61(6): 727-732.
23. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43(3): 396-402.